These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34719186)

  • 1. Development of Oral Tablet Formulation Containing Erlotinib: Randomly Methylated-β-cyclodextrin Inclusion Complex Using Direct Compression Method.
    Erdoğar N
    Turk J Pharm Sci; 2021 Oct; 18(5):589-596. PubMed ID: 34719186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib complexation with randomly methylated
    Erdoğar N; Akkın S; Varan G; Bilensoy E
    Pharm Dev Technol; 2021 Sep; 26(7):797-806. PubMed ID: 34219578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
    Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
    Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation.
    Ghorab MM; Abdel-Salam HM; El-Sayad MA; Mekhel MM
    AAPS PharmSciTech; 2004 Jul; 5(4):e59. PubMed ID: 15760056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex.
    Wang L; Zeng F; Zong L
    Pharm Dev Technol; 2013; 18(5):1101-10. PubMed ID: 22759202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes.
    Desai C; Prabhakar B
    Drug Dev Ind Pharm; 2015; 41(10):1589-607. PubMed ID: 25350555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
    Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
    Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and characterization of oral rapid disintegrating tablets of levocetirizine.
    Samvedna S; Jindal S; Mishra G; Madan JR; Gupta G; Awasthi R; Pinto TJA; Dua K; Kulkarni GT
    Polim Med; 2018; 48(1):31-40. PubMed ID: 30657656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of zaleplon complexation with cyclodextrins and hydrophilic polymers in solution and in solid state.
    Jablan J; Szalontai G; Jug M
    J Pharm Biomed Anal; 2012 Dec; 71():35-44. PubMed ID: 22898722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tablet formulation studies on an oxcarbazepine-beta cyclodextrin binary system.
    Patel NV; Chotai NP; Patel MP
    Pharmazie; 2008 Apr; 63(4):275-81. PubMed ID: 18468386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
    Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
    AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of β-cyclodextrin in the formulation of ODT tablets containing ibuprofen].
    Zimmer Ł; Kasperek R; Poleszak E
    Polim Med; 2014; 44(4):231-5. PubMed ID: 25932904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of fast dissolving tablets of oxaprozin based on hybrid systems of the drug with cyclodextrins and nanoclays.
    Maestrelli F; Mura P; Cirri M; Mennini N; Ghelardini C; Di Cesare Mannelli L
    Int J Pharm; 2017 Oct; 531(2):640-649. PubMed ID: 28522425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
    Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
    Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of inclusion complexation between fenoxaprop-p-ethyl and cyclodextrin.
    Zhang A; Liu W; Wang L; Wen Y
    J Agric Food Chem; 2005 Sep; 53(18):7193-7. PubMed ID: 16131129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative oral exemestane formulation: improved dissolution and permeation.
    Yavuz B; Bilensoy E; Vural I; Sumnu M
    Int J Pharm; 2010 Oct; 398(1-2):137-45. PubMed ID: 20678561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
    Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits.
    Aljimaee YH; El-Helw AR; Ahmed OA; El-Say KM
    Drug Des Devel Ther; 2015; 9():1379-92. PubMed ID: 25834396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosinopril-cyclodextrin inclusion complexes: phase solubility and physicochemical analysis.
    Sbârcea L; Udrescu L; Drăgan L; Trandafirescu C; Szabadai Z; Bojiţă M
    Pharmazie; 2011 Aug; 66(8):584-9. PubMed ID: 21901980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.